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INTRODUCTION
Tuberculosis (TB) is one of the most common
infectious disease in the world today, with 8 mil-
lion new cases and 2-3 million deaths occurring
annually [1-4]. This is projected to rise to almost
12 million cases by 2005. Over 95% of cases occur in
the developing world and TB causes approxi-
mately one quarter of all avoidable adult deaths
from infection [5].
The steady decline in cases of clinical tubercu-
losis seen in the developed, and parts of the devel-
oping, world ceased or reversed in the mid-1980s.
Case rates rose in the United States, particularly
New York and over much of Western Europe [3,6-
9]. Tuberculosis notifications levelled off or
increased in Eastern Europe and countries of the
former Soviet Union. In Western Europe these
trends reflected mainly the inflow of people from
high TB incidence countries and, in some settings,
HIV infection. The increasing rates of TB in Eastern
Europe mainly reflect problems in the national
control programs as a result of rapid political
transitions, non-standard treatment strategies
and socio-economic crises [2,3].
The highest estimated mortality occurs in sub-
Saharan Africa and South-East Asia. In contrast,
in the industrialized countries of Europe, America,
and Australia, the mortality rates are in general
less than two per 100000 population [1,2].
DRUG RESISTANT TUBERCULOSIS
Landmark trials conduced by the UK Medical
Research Council and others established the effi-
cacy of current multidrug combination chemother-
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apeutic regimens taken for periods of 6-12 months
depending on the location of disease; cure rates in
excess of 95% are possible but the effectiveness of
these standardized regimens is compromised when
drugs are taken inappropriately due to poor pati-
ent compliance [10-16]. Morbidity and mortality
are higher for drug resistant cases, particularly if
they are multiple drug resistant TB (MDRTB i.e.
resistant to isoniazid or rifampicin, e.g. [17]) and
there is co-infection with the HIV virus, e.g. [18-22].
Recent studies have demonstrated that survival
can be improved by the rapid application of drugs
to which the organism is susceptible, e.g. [23-26].
The real level of drug resistance in the world
today is unknown, although national and regional
studies and anecdotal evidence indicated that it
had been increasing in recent years [27-33]. The
emergence of MDRTB has refocused attention on
tuberculosis as a disease of continuing significance
in the developed and developing world. Unfortu-
nately, several methodological problems have
prevented the development of a clear global pic-
ture, including the absence of adequate culture
facilities, the use of nonstandardized methodo-
logies, the absence of quality control measures,
the absence of longitudinal studies to detect
trends, the failure of studies to differentiate pri-
mary and acquired drug resistance and the inher-
ent selection bias of many surveys, particularly
those centred on large studies and specialized
hospitals.
In a recent monograph, 63 representative drug
surveys performed around the world between
1985 and 1994 indicated that overall rates of pri-
mary drug resistance ranged from 0 to 16.9% for
isoniazid, from 0 to 3% for rifampicin, from 0 to
4.2% for ethambutol and 4.9% for streptomycin.
Acquired drug resistance rates were significantly
higher. Primary MDRTB rates ranged from 0 to
10.8%, but for acquired resistance the rate varied
from 0 to 48%. High levels of acquired MDRTB
were noted in New York City (30.1%), Bolivia
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Table 2 Countries/regions with a reported prevalance of
MDRTB greater than 3% among new cases
ethambutol and streptomycin, have been completed
by the network. In each round, identical sets of ten
isolates ofM. tuberculosis (20 cultures) are distributed
between all Supra-National Laboratories; the sam-
ple size was calculated to yield a significance level of
95% in order to be able to detect true differences
between laboratory methods with a power of 90%
[29,30,34]. The SRLs, in turn, supported national
surveys (or ongoingsurveillance) in their own coun-
tries and supported national reference laboratories
around the world in conducting surveys with the
national TB program. Regional networks of labora-
tories were formed in theWestern Pacific Region and
in Europe co-ordinated by the SRLs in London (UK)
Stockholm (Sweden), Paris (France) and Borstel
(Germany).
Fifty-four countries and 'geographic settings'
provided information on drug resistance in new
cases. Resistance to any drug was highest in Esto-
nia (36.9%), Henan Province in China (35.1%),
Ivanavo Oblast in Russia (32.4%), Latvia (29.9%)
Tomsk Oblast in Russia (29.0%) and Thailand
(25.5%) during the period 1996-9. The median pre-
valence in 1996-9 was 10.7% (range 1.7%-36.9%)
compared with a 9.9% prevalence for the 35 coun-
tries involved in the first phase of the project
reported in 1997 [27-30]. The median prevalence
of MDRTB was 1% (0-14.1 %) in the period 1996-9
compared with 1.4% in the first phase of the project
[29,30]. The highest MDRTB rates are given in
Table 2. Several countries, however, reported no
MDRTB in their surveys, e.g. Cuba, France, Kenya,
Finland, Switzerland, Uruguay and Venezuela. At
the other extreme, resistance to isoniazid, rifampi-
cin, streptomycin and ethambutol ranged from 0%
in 24 locations to 8.5% in Estonia. In general,
countries with poor NTPs had a higher prevalence
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Table 1 Prevalence of MDRTB in 12 countries (1994-97)
Combineda
Primary Acquired MDR
Country MDR (%) MDR (%) prevalence
Argentina 4.6 22.2 8.0
Dominican 6.6 19.7 8.6
Republic
Estonia 10.2 19.2 11.7
Ivory Coast 5.3
Latvia 14.4 54.4 22.1
Peru 2.5 15.7 4.5
Puerto Rico 1.9 13.6 2.6
Republic Korea 1.6 27.5 3.1
Romania 2.8 14.4 3.6
Russia 4.0 27.3 7.3
(Ivanovo Oblast)
USA 1.6 7.1 2.0
Zimbabwe 1.9 8.3 2.4
aprevalence of drug resistance regardless of history of
prior treatment. Adapted from WHO [29,30].
(15.3%), Korea (14.5%), Gujarat, India (33.8%) and
Nepal (48.0%) [33]. A recent report summarizing
trends in drug resistant TB rates in the USA, from
1993 to 1996, indicated that overall isoniazid resis-
tance was 8.4%, rifampicin 3.0% and MDRTB was
2.2% with the majority of MDRTB cases still occur-
ring in New York [31].
In 1994, the World Health Organization (WHO)
and International Union Against Tuberculosis and
Lung Disease (IUATLD) commenced the Global
Project on Anti-tuberculosis Drug Resistance Sur-
veillance, which reported in two monographs the
results of surveys and surveillance programs from
58 countries and geographic settings [29,30]. Data
from the first study is given in Table 1. The project
was designed to measure drug prevalence using
standardized methods guided by three overriding
principles, that: (a) the sample of TB patients must
be representative of cases within the whole coun-
try; (b) laboratory performance is validated; (c)
primary and acquired drug resistance can be dis-
tinguished. A key part of the program was the
creation of a Global Network of Supra-National
Reference Laboratories (SRLs) to serve as reference
centers for quality control of drug susceptibility
testing in national surveys. Currently, SRLs are
located in countries on most continents including
Canada, Australia, Argentina, the USA, the UK,
France, Germany, Sweden, Spain, Portugal, Bel-
gium, the Netherlands, Japan, Korea, South Africa,
Algeria and India. Seven quality control rounds,
focusing on resistance to isoniazid, rifampicin,
Country/region
Estonia
Henan Province (China)
Zhejiang Province (China)
Latvia
Tomsk Oblast (Russia)
Ivanovo Oblast (Russia)
Iran
Mozambique
Tamil Nadu (India)
Adapted from WHO [30].
% MDRTB
new cases
14.1
10.8
4.4
9.0
6.5
9.0
5.0
3.5
3.4
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of MDRTB. The use of standardized short course
chemotherapy (SSC) was associated with a lower
level of drug resistance. The properties and doses
of the principal anti-TB drugs available and recom-
mended are given in Table 3.
European countries have various degrees of
centralization of facilities for assaying drug resis-
Table 3 Front-line antituberculosis drugs in adults
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tance. In England and Wales, for example, most
hospital laboratories submit isolates of M. tubercu-
losis and other mycobacteria to the PHLS Myco-
bacterium Reference Unit or one of the other
Regional Centers for Mycobacteriology (RCM)
for speciation and drug susceptibility testing. A
system for the surveillance of drug resistance in
Intermittent
Drug Routea Daily Doseb Twice Weekly Thrice Weekly Major Side-effectsC Monitoringd
Isoniazid PO 300mg 15mg/kg 15mg/kg Peripheral neuropathy; LFT
1M 5mg/kg Max=900mg Max=900mg hepatitis, CNS effects, Levels of
IV increased phenytoin interacting
levels, interaction with drugs!
disulfiram hepatic
enzyme elevation
Rifampicin PO 600mg 10mg/kg 10mg/kg GI upset, hepatitis, LFT
IV 10mg/kg Max = 600 mg Max=600mg rash, bleeding Levels of
problems, contact lens interacting
and body fluids drugs
colored orange/pink;
decreases serum levels
of warfarin, methadone,
contraceptive hormone
level, dapsone,
ketoconazole,
theophylline, flu-like
syndrome
Pyrazinamide PO 1.5-2.5 g 2.5-3.5 g 2-3g GI upset, increase in LFT;
15-30mg/kg 50-70mg/kg 50-70mg/kg hepatic enzyme levels, Uric acid
rash, joint pain, (if needed)
hyperuricemia (gout
rarely), may complicate
control of diabetes
mellitus
Ethambutol PO 2.5 g (max) 50mg/kg 30mg/kg Red/green color Color vision,
15-25mg/kg blindness, optic neuritis, visual acuity
decreased visual activity,
rash
Streptomycine 1M 15mg/kg 25-30mg/kg 25mg/kg NephrotOXicity, Blood
IV ototoxicity, chemistry, renal
hypokalemia, function
hypomagnesemia audiometry
Reprinted from Drobniewski [35].
apossible routes of administration; in practice all drugs are given orally wherever possible.
bThe daily dose is quoted for a man of average weight; all doses are adjusted in accordance with a patient's weight.
clsoniazid causes the increased elimination of pyridoxine leading to peripheral neuropathy particularly in alcoholics, the
malnourished and during pregnancy. Daily doses of 10 mg per day are sufficient to compensate for this loss.
d LFT, liver function tests; specific monitoring points are given. At appropriate intervals the patient should be monitored
clinically, radiologically and bacteriologically. A full blood count including platelets should be performed if there is any
bleeding tendency.
eStreptomycin in patients over 60 years of age is more likely to lead to side-effects and daily doses should be limited to
10 mg/kg with a maximum dose of 750 mg. Closer observation of hearing loss and renal function may be necessary in this
age group.
!Aluminum based antacids reduce absorption.
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isolates of Mycobacterium tuberculosis, the UK
Mycobacterial Resistant Network (Mycobnet),
was established in 1993/4, linking all the principal
reference units in the UK. In initial isolates iso-
niazid and rifampicin, resistance rose from 4.6%
(157) to 6.1 % (221) and from 0.6% (22) to 1.8% (65),
respectively, from 1993 to 1996 [32]. Initial MDRTB
rates in the same period increased from 0.6% to
1.6% and combined clinical resistance or period
prevalence (the total level of resistance occurring
in one year) rose from 0.6% to 1.7% [32,36]. Resis-
tant TB cases were more likely to be seen in males,
those who have had previous TB, those who were
HIV positive (biased by outbreaks), those born
abroad and those in the black African ethnic group
and were lowest in the white ethnic group. Drug
resistant cases, by trend and absolute numbers,
occurred predominantly in London. Similar risk
factors apply with respect to increases in TB
incidence were seen in other West European
countries.
MEASURING DRUG RESISTANCE IN
MYCOBACTERIUM TUBERCULOSIS
Drug resistance occurs spontaneously in M. tuber-
culosis at a different rate for each drug. For exam-
ple, mutations resulting in resistance to rifampicin
occur at a rate of 10-10 per cell division and 10-7 to
10-9 for isoniazid. Overall, in drug-free environ-
ments this creates an estimated prevalance of
resistant organisms of 1 in 108 and 1 in 106, respec-
tively, for the two drugs. As lung cavities fre-
quently contain 107 bacilli, resistant bacilli
emerge naturally without antimicrobial pressure;
and mycobacterial drugs then select the resistant
population [37]. By the 1950s, it was established
that combination chemotherapy could prevent the
emergence of clinical resistance, which occurred
when patients were treated with a single drug.
Today, monodrug therapy occurs only when inap-
propriate chemoprophylaxis or treatment is given,
where there is poor adherence to therapy, an
irregular drug supply or drug malabsorption,
e.g. [38].
The lack of uniformity and reproducibility in the
methods used for antituberculosis drugs was first
noted in the late 1950s and 1960s. For isoniazid at
least eight different criteria for resistance were in
operation to define resistance. In studies that
examined the major methods available at the time,
significant differences were noted in the media
used, the inoculum size, minimum concentrations
of drug tested and the criteria used to establish
resistance. Symposia organized by the WHO and
the International Union Against Tuberculosis pro-
duced agreed definitions for drug resistance and
three categories of acceptable methods were
defined:
1. Absolute concentration (effectively minimum
inhibitory concentration).
2. The resistance ratio method.
3. The proportion method.
Detailed descriptions of these methods have
been published for first line drugs [39-43] and
more recently for second line drugs [44]. These
documents form the bedrock of drug susceptibility
testing for M. tuberculosis internationally.
International comparative studies in 1985 indi-
cated that there were no significant differences
between the absolute concentration and propor-
tion methods for isoniazid, rifampicin and para-
aminosalicylic acid (PAS), but they were not
always in agreement for streptomycin, ethambu-
tol, prothionamide (ethionamide), thiacetazone
[45]. The WHO Global Network of SRLs was
established to act as a quality control network
and to maintain a high level of proficiency in
the diagnosis of drug resistant tuberculosis. In
practice, all three principal methods perform ade-
quately, providing that the technical protocols
published are followed exactly [29,30].
The absolute concentration method
Drug is incorporated into solid agar or Lowensten-
Jensen medium as two-fold dilutions or used as a
broth-dilution method. Solid media methods are
more easily standardized. Resistance is defined as
the lowest concentration of the drug that inhibits
growth (less than 20 colonies). Drug concentra-
tions, and particularly inoculum size, must be
carefully standardized with reference to wild type
cultures. Variations in inoculum size are the major
source of error in this method [42,46].
The resistance ratio method
This is a refinement of the absolute concentration
method that controls for variations in the MIC of a
given isolate when tested on different batches of
drug-resistance media. It is defined as the MIC of
the test isolate divided by the MIC of a standard
susceptible strain such as H37Rv or by recently
© 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, eMI, 8
isolated susceptible wild-type strains. If the ratio is
two or less, or eight or more, the isolate is con-
sidered to be fully sensitive or highly resistant,
respectively. Intermediate or low level resistance is
difficult to measure accurately. Inoculum size
needs to be standardized but the critical concen-
tration does not need to be determined because of
the direct comparison with susceptible isolates
[42].
Proportion method
In this method, the strain is classified as suscep-
tible below a critical proportion of resistant bac-
teria and as resistant above it. The proportion
varies with different drugs, e.g. 1% for isoniazid
and rifampicin. This correlates with an effective
clinical outcome. In practical terms, the proportion
of drug resistant mutants comes from the ratio of
the number of colonies growing in drug-contain-
ing medium and on drug-free medium [39,40,46].
The introduction of the broth-based radiometric
BACTEC 460 method led to the development of
the proportion method for this system, using the
ratio of growth indices obtained by inoculation of
the test isolate in drug-containing medium and
inoculation of one-hundred fold dilution (1 %) of
the isolate in drug-free medium [47,48]. Standar-
dization of the inoculum is not as critical in this
method, although individual colonies must be
visible when using solid media.
Rapid non-radiometric automated culture
methods
Rapid non-radiometric automated culture meth-
ods are increasingly used for diagnosis, and stu-
dies using these systems to determine isoniazid
and rifampicin, in particular, drug resistance have
been published [49-51]. Their use is likely to
increase mainly in large reference centers due to
their higher cost when compared with solid cul-
ture-based methods. All use a modification of the
proportion method and require further develop-
ment if all first-line drugs are to be assayed. Most
studies have utilized indirect assays (i.e. the bac-
teria cultured first) with greatest success for iso-
niazid and rifampicin resistance measurement.
Smear-positive material, however, can be ana-
lyzed in direct assays on solid media and may
be almost as fast as indirect assays and are less
expensive. In regions where drug resistance is low,
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the increased cost of automated liquid culture
systems compared to routine testing on solid cul-
ture means that they are not likely to be cost-
effective. Capital costs are high and laboratory
containment facilities must be of the highest order,
which increases the costs further.
MOLECULAR METHODS FOR
DETECTING DRUG RESISTANCE
Novel molecular assays offer several potential
advantages, including faster turnaround times
and minimal, or possibly no, prior culture. Many
of the key gene mutations conferring resistance
have been identified, permitting the development
of in-house and commercial molecular assays [52-
63]. Considerable problems remain in the clinical
development of assays. The majority are more
costly than current methods, the exact proportion
of resistant organisms to susceptible organisms
producing resistance clinically is unclear and the
presence of common gene mutations is not always
associated with drug resistance (i.e. silent muta-
tions). Known or postulated genes involved in
drug resistance are described in Table 4.
Molecular drug assays can be divided into gen-
otypic (the drug target and nature of the gene
mutation is known) or phenotypic systems where
an outcome (i.e. death of the bacillus) is measured,
which does not require prior knowledge of the
underlying resistance mechanism.
Realistically, a combination of both types of
assays will be needed. Mutations within an 81-
bp region (codons 507-533) of the rpoB gene encod-
ing the beta chain of the DNA dependent RNA
polymerase, confers rifampicin resistance in
approximately 90-95% of all clinical isolates exam-
ined [59]. The presence of a mutation could be
detected by a genotypic assay and, in nearly all
cases, could be predictive of clinical drug resis-
tance. Isoniazid drug resistance, however, is more
complex, involving mutations in at least four genes
or gene complexes and not all mutations have
effects on the phenotype [52,54,55,61-63]. Insuffi-
cient information on the mechanism(s) of resis-
tance currently means that although the best
genotypic systems will predict rifampicin resis-
tance in 90-95% of cultures, they would fail to
predict real streptomycin, isoniazid and ciproflox-
acin resistance in approximately 40%,10-15% and
25% of isolates, respectively. Most genotypic
assays involve three main steps:
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Table 4 Molecular detection of drug resistance in Mycobacterium tuberculosis
Known or probable Mutations in genes
Drug targets conferring resistance Function of gene
Rifampicin RNA synthesis rpoB DNA dependent
RNA polynase
(jlsubunit)
Isoniazid Mycolic acid katG Catalase/ peroxidase
biosynthesis inhA/mabA Fatty acid biosynthesis
ahpC Alkylhydroperoxide C
reductase
oxyR Oxidative stress
regulator
Streptomycin Protein synthesis Rrs 16S r RNA
Rpsl ribosomal protein S12
Ethambutol Cell wall synthesis embA,B,C Lipoarabinomannan
and arabinogalactan
synthesis
Ethionamide Cell wall synthesis inhA +7 Cross resistance
associated with inh A
mutations
Pyrazinamide Pyrazinamidase pncA +7 Pyrazinamidase
Ciprofloxacin DNA Synthesis gyrA DNA gyrase
gyrB subunit A & B
(principally)
Adapted from Drobniewski and Pozniak [62] and Drobniewski and Wilson [63].
Molecular assays
PCR-SSCP Heteroduplex,
Line probe Sequencing
PCR-SSCP,
Sequencing
PCR-SSCP
Sequencing
Sequencing
Sequencing
PCR-SSCP
Sequencing
1. Sample preparation, which may be as simple as
mechanical disruption by boiling of a small
volume of cells in water, to full DNA purifica-
tion.
2. Amplification of the nucleic acid.
3. Detection of the mutation.
Once appropriate primers have been selected,
the region of interest can be amplified and muta-
tions detected as described below.
DNA sequencing
DNA sequencing is the gold standard, as all muta-
tions will be detected and, unless they are silent,
will be predictive of resistance. Automation has
simplified the process, bringing sequencing within
the capability of large academic and reference
centers, although they are expensive to purchase
and to operate. Automated analyzers using fluor-
escent chemistry methods can provide accurate
sequence data within 48 h. As Table 4 indicates,
automated sequencing has been used in the
research and clinical setting to identify mutations
for resistance to most first-line TB drugs, e.g.
[52-59].
Solid phase hybridization
From an understanding of the sequence in sensi-
tive and resistance strains, it is possible to design
probes that can be immobilized onto a membrane
support. Resistance can be detected by a reverse
hybridization principle [64]; i.e. a region of DNA in
which mutations are associated with drug resis-
tance can be amplified and allowed to hybridize
with the probes. Failure of binding is due to the
presence of a mutation and thus is predictive of
drug resistance. The principle has been used to dev-
elop commercial rifampicin-detection systems [65].
PCR-single-strand conformation polymorphism
PCR-single-strand conformation polymorphism
(PCR-SSPC) can be used as a manual or automated
system. It usually uses a radioactive detection sys-
tem but silver staining now offers a sensitive
alternative. Single-stranded DNA will fold into a
complex tertiary structure, whose shape is depen-
dent on the DNA sequence. If two single strands
of DNA differ by one or more bases, i.e. a muta-
tion, they will fold into structures with different
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mobilities on a polycrylamide gel, and can then be
detected, e.g. [59].
RNA assays
Assays for drug resistance and viability determi-
nation have been developed based on MRNA
detection through reverse transcription PCR
[66,67].
NOVEL PHENOTYPIC METHODS
Jacobs et a1. [68] showed that drug susceptibility
could be measured by the production of photons
by viable mycobacteria infected with phages
expressing the firefly luciferase gene. Untreated
mycobacteria or drug-resistant mycobacteria in
the presence of these latter drugs continue to
express luciferase, which catalyzes the reaction
of luciferin with ATP to generate photons of light.
Death of mycobacteria leads to cessation of light
production. This approach has the advantage that
no knowledge of the underlying genetic basis of
resistance is needed. Screening of novel antimy-
cobacterial drugs would also be simplified using
this technique. Although extremely attractive, the
assay has only recently been extended directly to
clinical specimens; requires approximately 105
bacilli/mL and relatively expensive equipment.
Recent research by the same group has reduced
the cost with the development of the 'Bronx Box',
in which the assay was developed into a microtitre
plate with a photographic film detection system
[69]. Current research to increase the sensitivity of
the assay and reduce the capital costs is under
development.
An alternative approach, the PhaB assay (phage
amplified biologically), involving mycobacter-
iophage without the need for expensive lumin-
ometers, has recently been described for the
diagnosis and detection of drug resistance. This
approach utilizes skills and resources that are
readily available within the diagnostic laboratory.
The PhaB assay can be used for the diagnosis of M.
tuberculosis in patient samples as well as the per-
formance of direct drug susceptibility testing of
organisms previously isolated by conventional
culture. The concept of the method is simple. In
the first step, a test culture or sample is infected
with mycobacteriophage. If there are viable myco-
bacteria in the sample they become infected with
mycobacteriophage. Subsequently, the mycobac-
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teriophage remammg outside the mycobacteria
are inactivated by a specific chemical treatment
whereas those inside the mycobacteria are pro-
tected. The protected mycobacteriophage then
replicate within viable bacilli and eventually cause
the host mycobacteria to lyze and release the new
generation of mycobacteriophage. The released
mycobacteriophage are plated onto a lawn of the
rapidly growing organism Mycobacterium smegma-
tis. The mycobacteriophages infect and replicate in
this related organism and, after an overnight incu-
bation, are detected as clear areas of lysis or pla-
ques in the turbid growth of the M. smegmatis
lawn. The procedure is potentially rapid and sim-
ple to perform, taking as little as 48 h compared to
the weeks required for conventional culture. The
sensitivity of the assay has been calculated to be as
few as 10-100 mycobacteria per mL of sample,
which is at least as sensitive as conventional cul-
ture. The assay involves the use of simple equip-
ment and as the assay proceeds, the number of
viable infectious M. tuberculosis particles actually
declines, so that unlike the systems described
above, the assay actually becomes safer with
increasing duration. In a recent evaluation the
assay correctly assigned and identified 8/8
000%) MDR isolates and 1/1 000%) rifampicin-
resistant/isoniazid-sensitive culture isolates.
When used to test the susceptibility to isoniazid,
the PhaB assay assigned 15/17 (88.2%) isoniazid-
resistant/rifampicin-sensitive isolates and 17/21
(81 %) isoniazid-sensitive isolates. The results were
obtained in 3-4 days but recent results suggest that
rifampicin-testing can be done in as little as 2 days
from receipt of a patient sample [69]. Correlation
with the resistance ratio method for streptomycin,
ethambutol and pyrazinamide was 96, 88 and 87%
[70]. Other simpler and less expensive assays
involving the use of dyes including Alamar blue
and MTT have shown promise [e.g 71].
CONCLUSION
This paper describes the available methods for
drug susceptibility testing for M. tuberculosis. They
have evolved over several decades and in most
European countries are performed in specialized
centers because they are technically demanding,
require appropriate isolation facilities, and can be
difficult to interpret. Methodology is becoming
standardized, although the results from the
WHO Global Programme on Drug Resistance in
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Tuberculosis has indicated the problems of repro-
ducibility that occur when inexperienced labora-
tories perform drug susceptibility testing, or
modify methods without a clear understanding
of the needs of standardization and quality con-
trol. The needs of clinical diagnostic centers to
report results at the earliest time has led to the
use of larger inocula and early reading of results,
which creates bias. Novel automated rapid culture
and molecular methods are under evaluation at
large reference centers. These centers are taking
part increasingly in international quality control
exerCIses.
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